Is Your AI Conversation Privileged?

​
May 8, 2026

‍

There are numerous AI tools available now that offer legal help, including drafting patent specifications, evaluating prior art, and preparing responses to office actions. Much has been said about the confidentiality of AI tools, you don’t want your AI tool to repeat your secrets (corporate or otherwise) to some stranger. But in the legal realm there is another concern, what if your opponent in litigation can demand access to your AI conversations.

Ordinarily, legal advice sought from a lawyer is privileged, it shouldn’t be available to an opponent in litigation. But what if you ask an AI tool for legal advice? Does using a tool that maintains privacy in the general sense protect you, or is that just as vulnerable in court?

Until recently these questions had no court-tested answer. But on the same day in February 2026, two US courts gave the first and, at first glance, opposite answers. The takeaway: an AI exchange that looks identical from the outside can be privileged in one party’s hands and discoverable in another's, depending on who set it up and how.

Heppner: When AI use sits outside the privileged relationship

In United States v. Heppner, Judge Rakoff of the Southern District of New York held that documents the defendant had generated using a public AI platform were not protected by attorney-client privilege. Bradley Heppner, anticipating a federal investigation, used a generative AI tool to draft multiple documents analyzing his potential defenses and legal exposure. He did this on his own initiative, before involving counsel, and only later shared the materials with his lawyers. Federal agents seized them in the execution of a search warrant.

The court held that no privilege attached, on three grounds. First, the AI tool was not a lawyer, and privilege requires communication with counsel. Second, the platform's terms of service permitted retention of inputs, use of those inputs to train the model, and disclosure to third parties including governmental authorities - meaning the defendant could have no reasonable expectation that what he shared would remain confidential. Third, the privilege test requires that the communication be for the purpose of obtaining legal advice. The court held that purpose was not met. No lawyer had directed Heppner to use the AI tool, so the use was not part of obtaining advice from counsel; and the platform's own terms disclaimed providing legal advice, undermining any claim that Heppner was seeking it from the tool itself.

The third point may be the most instructive. The court observed that "had counsel directed Heppner to use the AI tool, the tool might arguably be said to have functioned in a manner akin to a highly trained professional who may act as a lawyer's agent within the protection of the attorney-client privilege." This suggests the court was not hostile to AI in legal work; it was attentive to who was directing the work, in what relationship, and on what platform.

A footnote in the opinion adds a further caution. Even where information was originally privileged because it had been received from counsel, sharing it with the AI platform constituted disclosure to a third party and waived privilege as to that information. This waiver risk applies regardless of whether the user is the client or a non-lawyer team within the company.

Warner: Where work product is more forgiving

In Warner v. Gilbarco, decided the same day in the Eastern District of Michigan, a pro se plaintiff had used Chat GPT to prepare litigation materials. (A pro se plaintiff is someone who brings an action themselves without being represented by a lawyer.) The defendants moved to compel production of those materials. The court denied the motion, holding the materials were protected by the work-product doctrine.

Work product is a distinct protection from attorney-client privilege. It covers materials prepared in anticipation of litigation, and its waiver standard is meaningfully different. While disclosure of privileged information to a third party generally waives privilege, work-product waiver requires disclosure to an adversary, or in a manner that substantially increases the likelihood of adversary access. The court in Warner held that inputting materials into a generative AI platform did not meet that threshold, and was unconcerned that the platform "may have administrators somewhere in the background."

Warner therefore does not contradict Heppner. The two decisions apply different doctrines with different waiver standards, and they answer different questions. Together, they suggest that work product may survive AI use even where privilege would not, though the Heppner court's confidentiality analysis is a reminder that the platform's data terms could be vital, and the law in this area is still developing.

So should I avoid AI?

Read together, the cases suggest three considerations for whether work with AI is likely to be privileged:

1. the relationship within which the AI work was done;

2. the confidentiality policies of the platform on which it was done; and

3. the purpose for which it was done.

Where AI is used outside any attorney engagement, on a platform whose terms permit retention, training, and disclosure, and without an attorney  directing the work, Heppner shows that privilege can be lost.

On the other hand, where the use of AI addresses each of those concerns - qualified counsel using or directing AI use, on a platform configured to preserve confidentiality (e.g., no retention beyond what the engagement requires, no use of inputs for training, no third-party disclosure), for the purpose of providing legal advice, the analysis is materially different.

These are only the first cases on the topic. More will surely come, from more senior courts, and the law will develop case by case. And other countries may take different views from  the US. It would be premature to draw any firm conclusions, but already we have a useful guide.

From these two cases, the practical takeaways for patent drafting and prosecution are

i. make sure you know your (or your attorney’s) AI platform’s data terms; and

ii. AI use by registered patent attorneys  seems more likely to retain privilege than direct in-house (non-lawyer) use.

Visser AI, EIP's AI service for patent work, has been built around these considerations. The tools we use operate with zero data retention policies in place - meaning that not only is there no training on your data; the AI services do not retain your data at all.

Get in touch with Callum Docherty, or your usual EIP contact, if you’d like to learn more about Visser AI from EIP and Hybrid Intelligence. We can show you how we can improve outcomes and allow your patent budget to go further, while keeping your data secure.

The Latest Thought Leadership pieces in the Content Hub

No items found.
Stay in the Know

The Patent Strategist

Get expert insights and the top patent stories delivered straight to your inbox.

Heading
This is some text inside of a div block.
This is some text inside of a div block.

Latest Insights

Showing 0 of 100
Is Your AI Conversation Privileged?
08 May 2026
Recent US court decisions have, for the first time, tested whether conversations with AI tools can be protected by legal privilege. In United States v. Heppner, a court held that documents generated by a defendant using a public AI platform were not protected by attorney‑client privilege, largely because the AI was not used within a lawyer‑directed relationship and the platform’s terms allowed data retention and disclosure. By contrast, in Warner v. Gilbarco, another court found that AI‑assisted materials created by a self‑represented litigant were protected under the work‑product doctrine, which has a more forgiving standard for waiver.
#
Consulting
​
The evolution of nucleic acid sequencing and what it means for Genomics and IP
27 April 2026
This article outlines the evolution of nucleic acid sequencing, from early Sanger methods to next‑generation and long‑read technologies. The journey from deciphering individual DNA strands to sequencing entire genomes in hours represents one of biotechnology's most impressive transformations. The first human genome, completed through the Human Genome Project, took around 13 years to sequence and cost billions of dollars, whereas modern sequencing methods can now deliver a genome in hours for a few hundred dollars. For those interested in patents and life sciences, understanding the technical evolution of sequencing methods offers insights into how fundamental scientific advances translate into valuable patent portfolios.
#
Consulting
​
World IP Day: The big ideas shaping IP's fastest-moving fields
24 April 2026
For World IP Day, we asked experts of EIP’s five growth areas: Uniphy, Ampliphy, Stratiphy, Codiphy and Quantiphy, to share a quick insight on innovation, IP trends, and what excites them about the future. Each responded to a single, focused question reflecting the role their team plays across EIP.
#
Consulting
​
Meet the EIP team heading to INTA 2026 in London
23 April 2026
INTA's Annual Meeting is coming to London. From 2–6 May 2026, the ExCeL will host more than 10,000 trade mark and IP professionals from over 100 jurisdictions — five days of sessions, side events, and the kind of corridor conversations that turn into lasting working relationships.
#
Litigation
​
Antibody Patent Protection in Europe and the US: Navigating EPO and USPTO Differences
16 April 2026
This article explores the complexities of patenting antibody therapies, focusing on the differing requirements and practices of the European Patent Office (EPO) and the United States Patent and Trademark Office (USPTO). It highlights how the scope of claims, inventiveness standards, and supporting data requirements vary between jurisdictions, and explains why a tailored IP strategy is essential for innovators especially SMEs seeking protection in both Europe and the US. The article also outlines how EIP’s transatlantic teams collaborate to optimise patent applications for success in these key markets.
#
Patenting
​
Why competitor patent monitoring is critical to your drug development strategy
15 April 2026
This article explains why competitor IP monitoring is a critical part of an effective drug development strategy. By tracking competitor patent activity, companies can assess freedom to operate, identify risks and opportunities early, and make informed decisions on patent filings, licensing, and investment readiness. Ongoing monitoring also supports FTO analysis, third‑party observations, oppositions, and litigation strategy, helping life sciences businesses protect value and reduce risk throughout development.
#
Consulting
​
Biopharma Strategy in 2026: Lessons from 2025 on AI, M&A and the UPC
13 April 2026
This article looks back on a selection of key trends in the (bio)pharma industry in 2025 and looks ahead to how these may continue to develop into 2026.
#
Consulting
​
Thinking about IP from day one: strategic considerations for deep tech startups
08 April 2026
For deep tech startups, intellectual property decisions often come too late or cost too much too soon. This article explores why IP strategy should be considered from day one, even if formal protection comes later. It outlines how founders can decide what to patent, when trade secrets may be more appropriate, and how detectability, enforceability and cost should shape early choices. With a focus on practicality and commercial alignment, it also looks at how newer, AI‑assisted approaches can help startups take a more cost‑effective and flexible approach to building meaningful IP protection.
#
Consulting
​
National offices report increases in national patent applications throughout Europe: Is the EPO no longer “killing” the national offices?
27 March 2026
National patent offices across Europe have reported a marked increase in patent filings in 2025, breaking with a long‑standing downward trend. Data from Germany, France, Italy, Sweden, Austria, Spain and Norway point to growing activity driven by digital technologies, electrification and increased university participation. At the same time, offices report a rise in self‑drafted and AI‑assisted applications, which may lower barriers to entry but also raise concerns about application quality and examination efficiency.
#
Patenting
​
Make your bio(pharma) IP investment ready
22 March 2026
This recap of our LinkedIn Live series focuses on helping (bio)pharma businesses make their IP investment‑ready. Across three sessions, experts will discuss building resilient IP portfolios, making strategic IP decisions ahead of funding rounds, and what the evolving 2026 (bio)pharma landscape means for long‑term IP strategy.
#
Patenting
​
Are professional guidelines making Patent Attorneys too cautious on AI?
19 February 2026
As AI use accelerates in patent practice, many European patent attorneys remain cautious due to professional AI guidelines from the epi. This article argues those guidelines are not a barrier, but a baseline for responsible use.
#
Patenting
​
Provisional Agreement Reached on the EU Pharma Package: Takeaways for Pharmaceutical Companies
17 February 2026
The EU’s new Pharma Package will overhaul regulatory exclusivity, orphan drug incentives, antimicrobial innovation, and generic entry pathways, reducing standard protection periods while introducing new rewards like transferable exclusivity vouchers.
#
Patenting
​
Beyond CRISPR: Precision to Platform
23 January 2026
Gene editing is entering a new phase, moving beyond CRISPR-Cas9’s breakthrough but costly, bespoke therapies toward more precise and scalable platforms. While CRISPR-based treatments like Casgevy have proven clinical success, they remain expensive and entangled in ongoing patent disputes over foundational IP. Next-generation tools such as base editing and prime editing avoid double-strand DNA breaks, enabling more accurate corrections and broader therapeutic potential. The field’s focus is now shifting to disease-agnostic platforms that can be adapted across many conditions, improving access and efficiency.
#
Patenting
​
Confidentiality at the UPC: What litigants need to know
21 January 2026
This article explains how the Unified Patent Court approaches confidentiality in litigation, outlining the procedures for restricting access to sensitive information, how confidentiality clubs are formed, and when hearings may be held in private. It highlights key case law shaping these rules, the balance between fair trial rights and protection of commercial data, and the penalties for breaches. Practical guidance is provided to help parties navigate applications, manage confidential documents, and understand what to expect throughout UPC proceedings.
#
Litigation
​
EPO fees are going up in April 2026: Plan ahead now
19 January 2026
The European Patent Office will introduce a fee increase of roughly 5% from 1 April 2026, affecting search, examination, designation and renewal fees. Filing, excess page, opposition and appeal fees remain unchanged. Some costs—such as renewal fees—can be paid up to three months early, allowing applicants to secure the current lower rates. EIP recommends reviewing your portfolio ahead of the deadline.
#
Patenting
​